Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We continue to see substantial opportunity for growth given the broad label and the robust clinical profile of VOWST, which makes it an ideal choice for so many of the estimated 156,000 cases of recurrent CDI in the US each year |
| All of those lining up would make a very powerful story |
| As a result, we have confidence that we will ultimately achieve our goal of VOWST becoming a foundational therapy for our CDI, potentially reaching or surpassing the highest sales-based milestone threshold in the 2021 Nestle co-commercialization agreement of $750 million |
| These encouraging results align with our view that VOWST can become a foundational treatment for recurrent CDI and a highly significant commercial opportunity over time |
| Findings from that research support that HCPs remain highly receptive to the profile of VOWST and users have had a positive experience of taming patient access, supported by the Nestle field teams and the VOWST voyage patient hub |
| We believe positive data from this readout would further validate the promise of this novel therapeutic modality in addressing serious infections in medically vulnerable populations including patients with chronic liver disease, cancer neutropenia and solid organ transplant |
| These 2023 results since the launch of VOWST in June show the strong start of a significant opportunity to change the treatment paradigm across the entire rCDI patient pool |
| As we look forward into 2024, I'm excited about the continued success of VOWST, as well as the possibilities with SER-155 |
| As we do so, we believe we will be well positioned to create value for our shareholders and deliver our mission for patients now and in the future |
| One with a strong efficacy and safety profile as well as a convenient oral route of administration |
| Great progress about the hard work on the VOWST launch, very good |
| In partnership with Nestle Health Science, we are pleased with the broad patient access received thus far with more patients gaining access to VOWST than expected |
| So VOWST provides us a very strong proof of concept around the concept to be able to address infections in the gut |
| We are also seeing continued strong demand from a broad set of healthcare practitioners and across the recurrent C |
| I am extremely proud that we achieved over 2,000 VOWST patient starts in 2023 following our launch in June |
| As a result, demand continued to grow in the fourth quarter as reported to us by Nestle Health Science |
| I think that 155 will stand on its own with positive results |
| We look forward to seeing continued growth of VOWST utilization in 2024 and expect this positive trend to continue as patient outcomes on VOWST are more broadly recognized |
| In fact, our results exceeded our expectations across multiple dimensions |
| Finally, the hospital selling team continues its efforts to enhance hospital outflow, and we believe these efforts will accelerate demand in 2024 |
| So we believe actually both endpoints in terms of thinking about infections and the various ways we're looking at that as well as graft-versus-host disease are very well founded, and we've substantial preclinical and clinical data that support our drugs can have an impact there |
| The US launch of VOWST has exceeded our expectations |
| Our VOWST voyage hub continued to increase its successful conversion of enrollment to new patient starts in Q4 |
| I would say from our partners' perspective, I think we both are pleased with the launch to date |
| We are proud of the impact VOWST is having on patients, their families and the entire recurrent C |
| So we feel good about the patterns that we are seeing and that there is not a pattern other than the doctors choosing a high-risk patient, irrespective of number of recurrences |
| These additional opportunities have the potential to extend the utility of SER-155 and our preclinical stage pipeline and to establish a new approach in protecting immunocompromised patients from life-threatening infections and related clinical events |
| So we're very happy about scaling that promotion and look forward to the additional growth that we'll get this year as a result of it |
| Before opening the call up to Q&A, I would like to express how proud I am of the team at Seres and the team at Nestle for bringing a first-in-class oral therapy to the market |
| With the continued success of the VOWST launch and the clinical readout from SER-155 later this year, we look forward to 2024 as a year that will further validate Seres platform and the promise in microbiome therapeutics |
| Statement |
|---|
| In the fourth quarter specifically, that percentage was down -- was 44%, down from the 48% we reported for Q3 |
| As a reminder, the use of free drug that we are seeing is mostly due to patient affordability challenges with co-pays or other cost-sharing requirements after the prescription was approved by their insurer |
| This was an extremely difficult decision but a necessary one for positioning Seres optimally for the future |
| So you could imagine we might see some declines this year as payer policies are issued for the majority of the population |
| One is the domination of pathogens and the incidence of that in the gastrointestinal tract, particularly of Enterococcus and a couple of Enterobacteriaceae species that are particularly problematic in this patient population |
| Over time, as the VOWST pre-approval inventory is consumed, the magnitude of this profit component from the transfer of inventory will diminish |
| I mentioned that we saw the rate come down in Q4 from Q3, right? But we've got three quarters now in sort of the mid-40s |
| Last year, we made the difficult decision to restructure the company and focus on VOWST and SER-155 |
| We have said and I have said that we expect the utilization of these programs to go down, the voucher program will go down as we get policies on board |
| That said, that doesn't mean that we can't -- also can't be excited about what could potentially be opened up with a positive readout in the 155 study |
| The net sales reflect estimated gross to net reductions of approximately 11% |
| But specifically in 2025, with the IRA provisions going into effect, the patient assistance program, the more traditional path that we have that's income qualified in Medicare Part D patients, that's where we're seeing the majority of the utilization, that should really decline in 2025 |
| The total VOWST loss in the fourth quarter was $20.5 million, and our share of that was $10.3 million |
| Research and development expenses for the fourth quarter of 2023 were $26.8 million, reduced from $46.2 million for the same period in 2022 |
| Because the vast majority of this vast inventory was manufactured prior to approval, its cost was largely previously expensed and therefore, the inventory value is very low, resulting in the profit on the transfer of the VOWST inventory that is close to its supply price |
Please consider a small donation if you think this website provides you with relevant information